PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
- Overview – Merck & Co’s revenue growth will be fairly stable over the forecast period, as growth from Keytruda and Gardasil will be offset by declines from Januvia, Janumet, and the spin-off of Women’s Health and Legacy Brands.
- Key themes – [1] Keytruda will see strong growth over the forecast period until loss of exclusivity in 2028, although 2020 growth will be negatively impacted by two large price reductions in Japan [2] Merck’s metabolic portfolio will decline significantly due to patent expiries for key drugs Januvia and Janumet [3] Merck’s late-stage pipeline is heavily skewed towards label expansions for its existing oncology portfolio, with only a few new drug launches expected over the forecast period.
Model updates (27 October 2020)
- Keytruda forecast adjusted higher in the US due to lower impact from COVID-19 and broadening of revenue base beyond lung cancer
- Gardasil forecast adjusted lower due to continued COVID-19 impact in the US
- Januvia forecast adjusted higher due to stronger revenue trends.
Model updates (3 August 2020)
- Gardasil forecast adjusted lower due to COVID-19 impact in the US
- ProQuad forecast adjusted lower due to COVID-19 impact in the US
- Pneumovax 23 forecast adjusted lower due to COVID-19 impact in the US
- Keytruda forecast adjusted lower due to COVID-19 impact in the US and Europe.
Model updates (2 June 2020)
- Lenvima alliance revenue forecast adjusted higher
- NuvaRing forecast adjusted lower due to generic impact in the US.
Model updates (4 March 2020)
- Keytruda forecast adjusted lower due to 2020 impact of two significant price reductions in Japan
- Gardasil forecast adjusted higher due to strong demand globally
- Lenvima alliance revenue forecast added
- Lynparza alliance revenue forecast added
- Zetia forecast removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Vytorin removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- NuvaRing removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Implanon removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Singulair removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Cozaar removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Nasonex removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Arcoxia removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
- Follistim removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands.
Table of Contents
Company Background
Company Overview
Key Metrics
SWOT Analysis
Key Drug & Company Information
Company Comparison
Recent Earnings Review
Earnings Overview
Pharma Insights Analysis
Company Forecast
Prescription Pharmaceuticals Sales Outlook
Branded Drug Outlook
Launch Profile Outlook
Therapy Area Outlook
Regional Sales Outlook
Lifecycle Analysis
Company Profile
Marketed & Pipeline Drugs
Recent Events & Analyst Opinions
Upcoming Catalysts
Recent Insights
Clinical Trial Overview
Clinical Trial Snapshot
Clinical Trials by Country
Clinical Trials by Status and Phase
Clinical Trials by Drug